CA2446550A1 - Abuse-resistant controlled-release opioid dosage form - Google Patents
Abuse-resistant controlled-release opioid dosage form Download PDFInfo
- Publication number
- CA2446550A1 CA2446550A1 CA002446550A CA2446550A CA2446550A1 CA 2446550 A1 CA2446550 A1 CA 2446550A1 CA 002446550 A CA002446550 A CA 002446550A CA 2446550 A CA2446550 A CA 2446550A CA 2446550 A1 CA2446550 A1 CA 2446550A1
- Authority
- CA
- Canada
- Prior art keywords
- opioid
- antagonist
- pharmaceutical composition
- composition according
- blocking
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Abuse-resistant, controlled release opioid tablets in combination containing an opioid antagonist such as naloxone at a level above that needed to suppre ss the euphoric effect of the opioid, if the combination were crushed to break the controlled release properties causing the opioid and opioid antagonist t o be released as a immediate release product as a single dose. The controlled release nature of the table prevents the accumulation of orally effective amounts of opioid antagonist when taken normally. The opioid antagonist is contained in a controlled-release matrix and released, over time, with the opioid.
Claims (20)
1. An oral pharmaceutical composition comprising:
a controlled release matrix;
an opioid agonist;
an opioid antagonist having greater antagonistic effect when administered parenterally than when administered orally;
wherein said opioid antagonist is present in the composition in an orally effective amount for blocking the opioid effect and/or inducing withdrawal when the controlled release matrix is defeated and the composition improperly administered for immediate release;
wherein said controlled release matrix is selected and incorporated for controlling the release rate of the opioid antagonist such that antagonist levels are not effective for blocking the opioid effect by blocking both the inhibitory and excitatory receptors or for attenuating opioid side effects by selectively blocking the excitatory receptors under proper oral administration regimes.
a controlled release matrix;
an opioid agonist;
an opioid antagonist having greater antagonistic effect when administered parenterally than when administered orally;
wherein said opioid antagonist is present in the composition in an orally effective amount for blocking the opioid effect and/or inducing withdrawal when the controlled release matrix is defeated and the composition improperly administered for immediate release;
wherein said controlled release matrix is selected and incorporated for controlling the release rate of the opioid antagonist such that antagonist levels are not effective for blocking the opioid effect by blocking both the inhibitory and excitatory receptors or for attenuating opioid side effects by selectively blocking the excitatory receptors under proper oral administration regimes.
2. The pharmaceutical composition according to claim 1 wherein the release rate of the opioid antagonist is approximately 100 to approximately 25 percent of the release rate of the opioid agonist.
3. The pharmaceutical composition according to claim 1 wherein the release rate of the opioid antagonist is approximately 100 percent of the release rate of the opioid agonist.
4. The pharmaceutical composition according to claim 1 wherein the release rate of the opioid antagonist is approximately 50 percent of the release rate of the opioid agonist.
5. The pharmaceutical composition according to claim 1 wherein the release rate of the opioid antagonist is approximately 25 percent of the release rate of the opioid agonist.
6. The pharmaceutical composition according to claim 1 wherein the oral:parenteral potency ratio of the opioid antagonist is at least about 10:1.
7. The pharmaceutical composition according to claim 1 wherein the oral:parenteral potency ratio of the opioid antagonist is at least about 25:1.
8. The pharmaceutical composition according to claim 1 wherein the oral:parenteral potency ratio of the opioid antagonist is at least about 100:1.
9. The pharmaceutical composition according to claim 1, wherein said opioid agonist is selected from the group consisting of morphine, oxycodone, levorphenol, meperdine, hydrocodone, codeine, dihydrocodeine, hydromorphone, propoxyphene, methadone, and oxymorphone.
10. The pharmaceutical composition according to claim 1 wherein the opioid antagonist is selected from the group consisting of naloxone; naltrexone; N - cyclo propylmethyl - 7,8 -dihydro - 14- hydroxynormorphinone; and 21 - cyclopropyl z, - (1 - hydroxy - 1 - methylethyl) -6,14- endo - ethano - tetrahydrooripavine (or diphenorphine) and the pharmaceutically-acceptable salts thereof.
11. The pharmaceutical composition according to claim 1 wherein said opioid antagonist is naloxone.
12. The pharmaceutical composition according to claim 1 wherein said opioid agonist is oxycodone.
13. The pharmaceutical composition according to claim 1 wherein said opioid agonist is present in concentration pharmaceutically equivalent to oxycodone doses of approximately 10-160mg.
14. The pharmaceutical composition according to Claim 1, wherein the release rate of the antagonist is such that a single dose of the composition does not render available an orally effective amount of antagonist, yet when two or more doses of the composition are combined -with or without crushing - to achieve an abusive dose of the opioid agonist, the opioid antagonist is available at orally effective blocking levels.
15. A pharmaceutical composition comprising:
a controlled release matrix;
an opioid agonist;
an opioid antagonist having greater antagonistic effect when administered parenterally than when administered orally;
a controlled release matrix;
an opioid agonist;
an opioid antagonist having greater antagonistic effect when administered parenterally than when administered orally;
16 wherein said opioid antagonist is present in the composition in an amount proportional to the number of abusive doses of the opioid agonist in the composition such that if the CR matrix is defeated and two or more doses of the composition are combined to yield an abusive dose of the opioid agonist, the amount of opioid antagonist will suffice to block the opioid effect and/or induce withdrawal when taken orally;
wherein said controlled release matrix is selected and incorporated for controlling the release rate of the opioid antagonist such that antagonist levels are not effective for blocking the opioid effect by blocking the inhibitory and excitatory receptors or attenuating opioid side effects by selectively blocking the excitatory receptors under proper oral administration regimes.
16. The pharmaceutical composition according to Claim 15, wherein the release rate of the antagonist is such that a single dose of the composition does not render available an orally effective amount of antagonist, yet when two or more doses of the composition are combined -with or without crushing - to achieve an abusive dose of the opioid agonist, the opioid antagonist is available at orally effective blocking levels.
wherein said controlled release matrix is selected and incorporated for controlling the release rate of the opioid antagonist such that antagonist levels are not effective for blocking the opioid effect by blocking the inhibitory and excitatory receptors or attenuating opioid side effects by selectively blocking the excitatory receptors under proper oral administration regimes.
16. The pharmaceutical composition according to Claim 15, wherein the release rate of the antagonist is such that a single dose of the composition does not render available an orally effective amount of antagonist, yet when two or more doses of the composition are combined -with or without crushing - to achieve an abusive dose of the opioid agonist, the opioid antagonist is available at orally effective blocking levels.
17. An oral pharmaceutical composition comprising:
a controlled release matrix;
approximately 10-160 mg oxycodone;
approximately 2-160 mg naloxone;
wherein the ratio of oxycodone to naloxone is approximately 4-5:1 to 1:1;
wherein said controlled release matrix is selected and incorporated for controlling the release rate of the oxycodone for maintaining pharmaceutical effectiveness for a period up to 12 hours and for controlling the release rate of the naloxone such that naloxone levels are not effective for blocking the opioid effect by blocking both the inhibitory and excitatory receptors or for attenuating opioid side effects by selectively blocking the excitatory receptors under proper oral administration regimes.
a controlled release matrix;
approximately 10-160 mg oxycodone;
approximately 2-160 mg naloxone;
wherein the ratio of oxycodone to naloxone is approximately 4-5:1 to 1:1;
wherein said controlled release matrix is selected and incorporated for controlling the release rate of the oxycodone for maintaining pharmaceutical effectiveness for a period up to 12 hours and for controlling the release rate of the naloxone such that naloxone levels are not effective for blocking the opioid effect by blocking both the inhibitory and excitatory receptors or for attenuating opioid side effects by selectively blocking the excitatory receptors under proper oral administration regimes.
18. An oral pharmaceutical composition comprising, in % by weight:
about 3-35% opioid agonist;
about 2-20% opioid antagonist;
about 10-50% microcrystalline cellulose, NF;
about 30-70% ammonio methacrylate copolymer, NF; and at least one excipient selected from the group consisting of:
up to about 5% colloidal silicon dioxide, NF;
up to about 5% sodium lauryl sulfate, NF;
up to about 2% magnesium hydroxide, USP;
up to about 15% povidone, USP;
up to about 5% stearic acid, NF; and up to about 5% magnesium stearate, NF;
wherein said composition is a controlled release formulation adapted to release the oxycodone at a therapeutically effective rate, and to release said naloxone at a rate ineffective for blocking the opioid effect and/or inducing withdrawal when the controlled release formulation is taken orally in intact form.
about 3-35% opioid agonist;
about 2-20% opioid antagonist;
about 10-50% microcrystalline cellulose, NF;
about 30-70% ammonio methacrylate copolymer, NF; and at least one excipient selected from the group consisting of:
up to about 5% colloidal silicon dioxide, NF;
up to about 5% sodium lauryl sulfate, NF;
up to about 2% magnesium hydroxide, USP;
up to about 15% povidone, USP;
up to about 5% stearic acid, NF; and up to about 5% magnesium stearate, NF;
wherein said composition is a controlled release formulation adapted to release the oxycodone at a therapeutically effective rate, and to release said naloxone at a rate ineffective for blocking the opioid effect and/or inducing withdrawal when the controlled release formulation is taken orally in intact form.
19. The oral pharmaceutical composition according to claim 18, wherein said opioid agonist is selected from the group consisting of morphine, oxycodone, levorphenol, meperdine, hydrocodone, codeine, dihydrocodeine, hydromorphone, propoxyphene, methadone, and oxymorphone and the opioid antagonist is selected from the group consisting of naloxone;
naltrexone; N - cyclo propylmethyl - 7,8 - dihydro - 14- hydroxynormorphinone;
and 21 -cyclopropyl z, - (1 - hydroxy - 1 - methylethyl) - 6,14- endo - ethano -tetrahydrooripavine (or diphenorphine) and the pharmaceutically-acceptable salts thereof.
naltrexone; N - cyclo propylmethyl - 7,8 - dihydro - 14- hydroxynormorphinone;
and 21 -cyclopropyl z, - (1 - hydroxy - 1 - methylethyl) - 6,14- endo - ethano -tetrahydrooripavine (or diphenorphine) and the pharmaceutically-acceptable salts thereof.
20. The oral pharmaceutical composition according to claim 18 wherein said opioid agonist is oxycodone hydrochloride and said opioid antagonist is naloxone.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29043901P | 2001-05-11 | 2001-05-11 | |
US60/290,439 | 2001-05-11 | ||
PCT/US2002/015022 WO2002092060A1 (en) | 2001-05-11 | 2002-05-10 | Abuse-resistant controlled-release opioid dosage form |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2446550A1 true CA2446550A1 (en) | 2002-11-21 |
CA2446550C CA2446550C (en) | 2012-03-06 |
Family
ID=23116001
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2446550A Expired - Lifetime CA2446550C (en) | 2001-05-11 | 2002-05-10 | Abuse-resistant controlled-release opioid dosage form |
Country Status (10)
Country | Link |
---|---|
US (20) | US20030065002A1 (en) |
EP (1) | EP1387673B1 (en) |
JP (7) | JP4522652B2 (en) |
CN (1) | CN1525851A (en) |
AT (1) | ATE493130T1 (en) |
AU (2) | AU2002305559B2 (en) |
CA (1) | CA2446550C (en) |
DE (1) | DE60238756D1 (en) |
ES (1) | ES2361148T3 (en) |
WO (1) | WO2002092060A1 (en) |
Families Citing this family (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
WO1999032119A1 (en) | 1997-12-22 | 1999-07-01 | Euro-Celtique, S.A. | Opioid agonist/antagonist combinations |
HU229705B1 (en) * | 2000-02-08 | 2014-05-28 | Euro Celtique Sa | Tamper-resistant oral opioid agonist formulations |
ATE493130T1 (en) * | 2001-05-11 | 2011-01-15 | Endo Pharmaceuticals Inc | MEDICINAL FORM CONTAINING OPIOID AGAINST ABUSE |
ES2275868T3 (en) * | 2001-05-11 | 2007-06-16 | Endo Pharmaceuticals Inc. | OPIOID DOSAGE FORM TO PREVENT ABUSIVE CONSUMPTION. |
CN1610551A (en) | 2001-07-06 | 2005-04-27 | 恩德制药公司 | Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic |
ATE376832T1 (en) * | 2001-07-06 | 2007-11-15 | Penwest Pharmaceuticals Co | DELAYED RELEASE FORMULATIONS OF OXYMORPHONE |
US8329216B2 (en) | 2001-07-06 | 2012-12-11 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
DE60230632D1 (en) * | 2001-07-18 | 2009-02-12 | Euro Celtique Sa | PHARMACEUTICAL COMBINATIONS OF OXYCODONE AND NALOXONE |
WO2003026743A2 (en) * | 2001-09-26 | 2003-04-03 | Penwest Pharmaceuticals Company | Opioid formulations having reduced potential for abuse |
EP2939696B1 (en) | 2001-10-18 | 2016-03-09 | Nektar Therapeutics | Polymer conjugates of opioid antagonists |
EP2243471A1 (en) | 2002-04-05 | 2010-10-27 | Euro-Celtique S.A. | Matrix for sustained, invariant and independent release of active compounds |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
DK1551372T3 (en) * | 2002-09-20 | 2018-07-23 | Alpharma Pharmaceuticals Llc | SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES |
JP5189242B2 (en) * | 2002-09-23 | 2013-04-24 | アルケルメス ファーマ アイルランド リミテッド | Abuse-resistant pharmaceutical composition |
US20040202717A1 (en) | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
TWI347201B (en) | 2003-04-21 | 2011-08-21 | Euro Celtique Sa | Pharmaceutical products,uses thereof and methods for preparing the same |
US8790689B2 (en) | 2003-04-30 | 2014-07-29 | Purdue Pharma L.P. | Tamper resistant transdermal dosage form |
US7182955B2 (en) | 2003-04-30 | 2007-02-27 | 3M Innovative Properties Company | Abuse-resistant transdermal dosage form |
US8778382B2 (en) | 2003-04-30 | 2014-07-15 | Purdue Pharma L.P. | Tamper resistant transdermal dosage form |
DE10361596A1 (en) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
DE102005005446A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Break-resistant dosage forms with sustained release |
DE10336400A1 (en) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Anti-abuse dosage form |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
KR101053558B1 (en) | 2004-03-30 | 2011-08-03 | 유로-셀띠끄 소시에떼 아노님 | Tamper resistant dosage form comprising an adsorbent and an adverse agent |
EP1604667A1 (en) * | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the restless leg syndrome |
EP1604666A1 (en) | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD) |
DE102004032049A1 (en) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Anti-abuse, oral dosage form |
US7827983B2 (en) * | 2004-12-20 | 2010-11-09 | Hewlett-Packard Development Company, L.P. | Method for making a pharmaceutically active ingredient abuse-prevention device |
DE102005005449A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
EP1702558A1 (en) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Method and device for the assessment of bowel function |
EP1695700A1 (en) * | 2005-02-28 | 2006-08-30 | Euro-Celtique S.A. | Dosage form containing oxycodone and naloxone |
GB0506982D0 (en) * | 2005-04-06 | 2005-05-11 | Mw Encap Ltd | Abuse resistant capsules |
US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
AU2006326377B2 (en) * | 2005-12-13 | 2010-10-07 | Biodelivery Sciences International, Inc. | Abuse resistant transmucosal drug delivery device |
EP1810678A1 (en) | 2006-01-19 | 2007-07-25 | Holger Lars Hermann | Use of morphine and naloxone for drug substitution |
US20070185145A1 (en) * | 2006-02-03 | 2007-08-09 | Royds Robert B | Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same |
US20070212414A1 (en) * | 2006-03-08 | 2007-09-13 | Penwest Pharmaceuticals Co. | Ethanol-resistant sustained release formulations |
US8916195B2 (en) * | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
CN101677963B (en) | 2006-06-19 | 2012-05-30 | 奥尔制药公司 | Pharmaceutical compositions |
KR101230804B1 (en) | 2006-07-21 | 2013-02-08 | 바이오딜리버리 사이언시스 인터내셔널 인코포레이티드 | Transmucosal delivery devices with enhanced uptake |
SA07280459B1 (en) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic |
DE202006018609U1 (en) * | 2006-08-29 | 2007-05-16 | Euro-Celtique S.A. | Needle-free apparatus for administrating pharmaceutical composition in humans, comprises a housing; auxiliary substance to force a pharmaceutical composition from a package into human body; a composition comprising analgesic, e.g. opioids |
EP1897543A1 (en) | 2006-08-30 | 2008-03-12 | Euro-Celtique S.A. | Buprenorphine- wafer for drug substitution therapy |
DK2101740T3 (en) | 2006-12-04 | 2013-11-18 | Orexo Ab | NEW NON-ABUSE PHARMACEUTICAL COMPOSITIONS COMPREHENSIVE OPIOIDS |
US20090124650A1 (en) * | 2007-06-21 | 2009-05-14 | Endo Pharmaceuticals, Inc. | Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol |
US20100151014A1 (en) * | 2008-12-16 | 2010-06-17 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
AU2008346870A1 (en) * | 2007-12-17 | 2009-07-16 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
JP5651818B2 (en) | 2007-12-17 | 2015-01-14 | パラディン ラブス インコーポレーテッド | Controlled release formulation to prevent misuse |
US8623418B2 (en) * | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
AU2009207796B2 (en) | 2008-01-25 | 2014-03-27 | Grunenthal Gmbh | Pharmaceutical dosage form |
BRPI0910780A2 (en) * | 2008-07-07 | 2016-08-09 | Euro Celtique Sa | use of opioid antagonists for the treatment of urinary retention |
ES2414856T3 (en) * | 2008-12-12 | 2013-07-23 | Paladin Labs Inc. | Narcotic drug formulations with decreased addiction potential |
CA2746888C (en) | 2008-12-16 | 2015-05-12 | Labopharm (Barbados) Limited | Misuse preventative, controlled release formulation |
BRPI0923836A2 (en) | 2008-12-31 | 2015-07-21 | Upsher Smith Lab Inc | Opioid-containing oral pharmaceutical compositions and methods |
DK2405915T3 (en) | 2009-03-10 | 2019-02-11 | Euro Celtique Sa | PHARMACEUTICAL COMPOSITIONS WITH IMMEDIATE RELEASE INCLUDING OXYCODON AND NALOXON |
US20110097401A1 (en) * | 2009-06-12 | 2011-04-28 | Meritage Pharma, Inc. | Methods for treating gastrointestinal disorders |
NZ596667A (en) | 2009-07-22 | 2013-09-27 | Gruenenthal Chemie | Hot-melt extruded controlled release dosage form |
PT2456424E (en) | 2009-07-22 | 2013-09-30 | Gruenenthal Gmbh | Oxidation-stabilized tamper-resistant dosage form |
EP2477610A1 (en) | 2009-09-17 | 2012-07-25 | Upsher-Smith Laboratories, Inc. | A sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti -inflammatory drug |
MX349145B (en) * | 2010-03-11 | 2017-07-14 | Wyeth Llc * | Oral formulations and lipophilic salts of methylnaltrexone. |
ES2642788T3 (en) | 2010-05-10 | 2017-11-20 | Euro-Celtique S.A. | Manufacture of granules without active substance and tablets comprising the same |
ES2408343B2 (en) | 2010-05-10 | 2014-07-17 | Euro-Celtique, Sa | Pharmaceutical compositions comprising hydromorphone and naloxone |
NZ603170A (en) | 2010-05-10 | 2015-04-24 | Euro Celtique Sa | Combination of active loaded granules with additional actives |
CA2808541C (en) | 2010-09-02 | 2019-01-08 | Gruenenthal Gmbh | Tamper resistant dosage form comprising an anionic polymer |
MX2013002377A (en) | 2010-09-02 | 2013-04-29 | Gruenenthal Gmbh | Tamper resistant dosage form comprising inorganic salt. |
MX348054B (en) | 2011-07-29 | 2017-05-25 | Gruenenthal Gmbh | Tamper-resistant tablet providing immediate drug release. |
AR087360A1 (en) | 2011-07-29 | 2014-03-19 | Gruenenthal Gmbh | PROOF OF HANDLING TABLET PROVIDING IMMEDIATE RELEASE OF PHARMACY |
US20130071477A1 (en) | 2011-09-19 | 2013-03-21 | Orexo Ab | New abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
MX349725B (en) * | 2011-11-17 | 2017-08-10 | Gruenenthal Gmbh | Tamper-resistant oral pharmaceutical dosage form comprising a pharmacologically active ingredient, an opioid antagonist and/or aversive agent, polyalkylene oxide and anionic polymer. |
US9901539B2 (en) | 2011-12-21 | 2018-02-27 | Biodelivery Sciences International, Inc. | Transmucosal drug delivery devices for use in chronic pain relief |
AU2013225106B2 (en) | 2012-02-28 | 2017-11-02 | Grunenthal Gmbh | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
CA3120681A1 (en) | 2012-04-17 | 2013-10-24 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
RS57913B1 (en) | 2012-04-18 | 2019-01-31 | Gruenenthal Gmbh | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
ES2698611T3 (en) | 2012-07-12 | 2019-02-05 | SpecGx LLC | Pharmaceutical compositions dissuasive of abuse and prolonged release |
US10322120B2 (en) | 2012-07-31 | 2019-06-18 | Persion Pharmaceuticals Llc | Treating pain in patients with hepatic impairment |
US9675587B2 (en) * | 2013-03-14 | 2017-06-13 | Allergan Holdings Unlimited Company | Opioid receptor modulator dosage formulations |
JP6466417B2 (en) | 2013-05-29 | 2019-02-06 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | A tamper-resistant dosage form with a bimodal release profile |
JP6445537B2 (en) | 2013-05-29 | 2018-12-26 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Tamper-resistant dosage forms containing one or more particles |
JP6449871B2 (en) | 2013-07-12 | 2019-01-09 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Anti-modified dosage form containing ethylene-vinyl acetate polymer |
KR20180037074A (en) | 2013-07-23 | 2018-04-10 | 유로-셀티큐 에스.에이. | A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation |
EP3062778A4 (en) * | 2013-10-31 | 2017-07-19 | Cima Labs Inc. | Immediate release abuse-deterrent granulated dosage forms |
US20150118300A1 (en) * | 2013-10-31 | 2015-04-30 | Cima Labs Inc. | Immediate Release Abuse-Deterrent Granulated Dosage Forms |
KR102194174B1 (en) | 2013-11-13 | 2020-12-23 | 유로-셀티큐 에스.에이. | Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome |
BR112016010482B1 (en) | 2013-11-26 | 2022-11-16 | Grünenthal GmbH | PREPARATION OF A PHARMACEUTICAL COMPOSITION IN POWDER BY MEANS OF CRYOMING |
WO2015173195A1 (en) | 2014-05-12 | 2015-11-19 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
JP2017516789A (en) | 2014-05-26 | 2017-06-22 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Multiparticulates protected against ethanol overdose |
US9849124B2 (en) | 2014-10-17 | 2017-12-26 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
EA035434B1 (en) | 2015-04-24 | 2020-06-15 | Грюненталь Гмбх | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
US10842750B2 (en) | 2015-09-10 | 2020-11-24 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
US9943513B1 (en) | 2015-10-07 | 2018-04-17 | Banner Life Sciences Llc | Opioid abuse deterrent dosage forms |
US10335405B1 (en) | 2016-05-04 | 2019-07-02 | Patheon Softgels, Inc. | Non-burst releasing pharmaceutical composition |
US11541125B2 (en) | 2016-12-19 | 2023-01-03 | The Regents Of The University Of California | Noncrushable pill formulations |
US10335375B2 (en) | 2017-05-30 | 2019-07-02 | Patheon Softgels, Inc. | Anti-overingestion abuse deterrent compositions |
EP3965733A4 (en) | 2019-05-07 | 2023-01-11 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
Family Cites Families (269)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2770569A (en) | 1952-08-01 | 1956-11-13 | Hoffmann La Roche | Analgesic compositions |
US3173877A (en) | 1957-09-09 | 1965-03-16 | Wyandotte Chemicals Corp | Detergent compositions comprising inorganic esters of epoxyhydrocarbon polymers |
US3173876A (en) | 1960-05-27 | 1965-03-16 | John C Zobrist | Cleaning methods and compositions |
NL271831A (en) | 1960-11-29 | |||
US3493657A (en) | 1961-03-14 | 1970-02-03 | Mozes Juda Lewenstein | Therapeutic compositions of n-allyl-14-hydroxy - dihydronormorphinane and morphine |
US3332950A (en) | 1963-03-23 | 1967-07-25 | Endo Lab | 14-hydroxydihydronormorphinone derivatives |
US3276586A (en) | 1963-08-30 | 1966-10-04 | Rosaen Filter Co | Indicating means for fluid filters |
NL6714885A (en) | 1967-11-02 | 1969-05-06 | ||
US3541006A (en) | 1968-07-03 | 1970-11-17 | Amicon Corp | Ultrafiltration process |
US3541005A (en) | 1969-02-05 | 1970-11-17 | Amicon Corp | Continuous ultrafiltration of macromolecular solutions |
US3773955A (en) | 1970-08-03 | 1973-11-20 | Bristol Myers Co | Analgetic compositions |
US3879555A (en) | 1970-11-16 | 1975-04-22 | Bristol Myers Co | Method of treating drug addicts |
US3676557A (en) | 1971-03-02 | 1972-07-11 | Endo Lab | Long-acting narcotic antagonist formulations |
GB1390772A (en) | 1971-05-07 | 1975-04-16 | Endo Lab | Oral narcotic composition |
FR2183546B1 (en) | 1972-05-10 | 1975-06-20 | Servier Lab | |
US3965256A (en) | 1972-05-16 | 1976-06-22 | Synergistics | Slow release pharmaceutical compositions |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US3916889A (en) | 1973-09-28 | 1975-11-04 | Sandoz Ag | Patient ventilator apparatus |
US3966940A (en) * | 1973-11-09 | 1976-06-29 | Bristol-Myers Company | Analgetic compositions |
GB1478759A (en) | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
US3966040A (en) | 1975-03-05 | 1976-06-29 | Hazelwood John E | Combined vibratory feeder drive unit, vibratory feeder bowl, and parts separator |
US4077407A (en) | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
US4126684A (en) | 1976-02-11 | 1978-11-21 | Ciba-Geigy Corporation | 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse |
US4063064A (en) | 1976-02-23 | 1977-12-13 | Coherent Radiation | Apparatus for tracking moving workpiece by a laser beam |
LU77339A1 (en) * | 1977-05-16 | 1979-01-19 | ||
US4176186A (en) | 1978-07-28 | 1979-11-27 | Boehringer Ingelheim Gmbh | Quaternary derivatives of noroxymorphone which relieve intestinal immobility |
US4285987A (en) | 1978-10-23 | 1981-08-25 | Alza Corporation | Process for manufacturing device with dispersion zone |
US4200098A (en) | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
US4237140A (en) | 1979-05-18 | 1980-12-02 | E. I. Du Pont De Nemours And Company | Analgesic mixture of nalbuphine and acetaminophen |
US4293539A (en) | 1979-09-12 | 1981-10-06 | Eli Lilly And Company | Controlled release formulations and method of treatment |
IE49324B1 (en) | 1979-12-19 | 1985-09-18 | Euro Celtique Sa | Controlled release compositions |
US4457933A (en) * | 1980-01-24 | 1984-07-03 | Bristol-Myers Company | Prevention of analgesic abuse |
IE53363B1 (en) * | 1981-02-12 | 1988-10-26 | Wyeth John & Brother Ltd | Treating shock using meptazinol |
US4464378A (en) | 1981-04-28 | 1984-08-07 | University Of Kentucky Research Foundation | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same |
US4401672A (en) | 1981-10-13 | 1983-08-30 | Regents Of The University Of Minnesota | Non-addictive narcotic antitussive preparation |
US4608376A (en) | 1981-10-16 | 1986-08-26 | Carolyn McGinnis | Opiate agonists and antagonists |
DE3381877D1 (en) | 1982-03-16 | 1990-10-18 | Univ Rockefeller | USE OF OPIUM ANTAGONISTS FOR THE PRODUCTION OF MEDICINAL PRODUCTS FOR THE REMEDY OF GASTRO-INTESTINAL DISORDERS. |
US4987136A (en) | 1982-03-16 | 1991-01-22 | The Rockefeller University | Method for controlling gastrointestinal dysmotility |
US4443428A (en) | 1982-06-21 | 1984-04-17 | Euroceltique, S.A. | Extended action controlled release compositions |
US4451470A (en) | 1982-07-06 | 1984-05-29 | E. I. Du Pont De Nemours And Company | Analgesic, antagonist, and/or anorectic 14-fluoromorphinans |
US4803208A (en) | 1982-09-30 | 1989-02-07 | Sloan-Kettering Institute For Cancer Research | Opiate agonists and antagonists |
GB8332556D0 (en) | 1983-12-06 | 1984-01-11 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
US5266574A (en) | 1984-04-09 | 1993-11-30 | Ian S. Zagon | Growth regulation and related applications of opioid antagonists |
US4668685A (en) | 1984-07-05 | 1987-05-26 | E.I. Du Pont De Nemours And Company | Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists |
DE3434946A1 (en) | 1984-09-22 | 1986-04-03 | Basf Ag, 6700 Ludwigshafen | DIARYLACETYLENE, THEIR PRODUCTION AND USE |
US4573995A (en) | 1984-10-09 | 1986-03-04 | Alza Corporation | Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine |
GB8430346D0 (en) | 1984-11-30 | 1985-01-09 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
US4806341A (en) | 1985-02-25 | 1989-02-21 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration |
ZA861211B (en) | 1985-02-25 | 1987-10-28 | Lilly Co Eli | Analgesic composition |
GB8514665D0 (en) | 1985-06-11 | 1985-07-10 | Eroceltique Sa | Oral pharmaceutical composition |
FR2585246A1 (en) | 1985-07-26 | 1987-01-30 | Cortial | PROCESS FOR OBTAINING SOLID PHARMACEUTICAL FORMS WITH PROLONGED RELEASE |
GB8521350D0 (en) | 1985-08-28 | 1985-10-02 | Euro Celtique Sa | Analgesic composition |
DE3687575T2 (en) | 1985-09-06 | 1993-07-01 | Baker Norton Pharma | USE OF 6-METHYLENE-6-DESOXY-N-CYCLOPROPYLMETHYL-14-HYDROXYDIHYDRONORMORPHINE. |
US4889860A (en) | 1985-09-23 | 1989-12-26 | Nova Pharmaceutical Corporation | Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists |
US4760069A (en) | 1985-09-23 | 1988-07-26 | Nova Pharmaceutical Corporation | Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists |
US4722928A (en) | 1985-12-02 | 1988-02-02 | E. I. Du Pont De Nemours And Company | N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans having improved oral bioavailability, pharmaceutical compositions, and processes |
US4730048A (en) | 1985-12-12 | 1988-03-08 | Regents Of The University Of Minnesota | Gut-selective opiates |
US4861781A (en) | 1986-03-07 | 1989-08-29 | The University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
US4719215A (en) | 1986-03-07 | 1988-01-12 | University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
US5316759A (en) | 1986-03-17 | 1994-05-31 | Robert J. Schaap | Agonist-antagonist combination to reduce the use of nicotine and other drugs |
GB8613688D0 (en) | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB8613689D0 (en) | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
EP0249347B1 (en) | 1986-06-10 | 1994-06-29 | Euroceltique S.A. | Controlled release dihydrocodeine composition |
US4785000A (en) | 1986-06-18 | 1988-11-15 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
US4769372A (en) | 1986-06-18 | 1988-09-06 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
US4861598A (en) | 1986-07-18 | 1989-08-29 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
US4970075A (en) | 1986-07-18 | 1990-11-13 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
US5356900A (en) | 1986-10-07 | 1994-10-18 | Bernard Bihari | Method of treating chronic herpes virus infections using an opiate receptor antagonist |
GB8626098D0 (en) | 1986-10-31 | 1986-12-03 | Euro Celtique Sa | Controlled release hydromorphone composition |
US4806543A (en) | 1986-11-25 | 1989-02-21 | Board Of Trustees Of The Leland Stanford Junior University | Method and compositions for reducing neurotoxic injury |
GB8628728D0 (en) | 1986-12-02 | 1987-01-07 | Euro Celtique Sa | Spheroids |
GB8705083D0 (en) | 1987-03-04 | 1987-04-08 | Euro Celtique Sa | Spheroids |
GB8728294D0 (en) | 1987-12-03 | 1988-01-06 | Reckitt & Colmann Prod Ltd | Treatment compositions |
DE3812567A1 (en) | 1988-04-15 | 1989-10-26 | Basf Ag | METHOD FOR PRODUCING PHARMACEUTICAL MIXTURES |
US4873076A (en) | 1988-04-29 | 1989-10-10 | Baker Cummins Pharmaceuticals, Inc. | Method of safely providing anesthesia or conscious sedation |
GB8813064D0 (en) | 1988-06-02 | 1988-07-06 | Euro Celtique Sa | Controlled release dosage forms having defined water content |
US4882335A (en) | 1988-06-13 | 1989-11-21 | Alko Limited | Method for treating alcohol-drinking response |
EP0352361A1 (en) | 1988-07-29 | 1990-01-31 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
US5236714A (en) | 1988-11-01 | 1993-08-17 | Alza Corporation | Abusable substance dosage form having reduced abuse potential |
CA2002492A1 (en) | 1988-11-11 | 1990-05-11 | Sandra T. A. Malkowska | Pharmaceutical ion exchange resin composition |
US5102887A (en) | 1989-02-17 | 1992-04-07 | Arch Development Corporation | Method for reducing emesis and nausea induced by the administration of an emesis causing agent |
US5096715A (en) | 1989-11-20 | 1992-03-17 | Alko Ltd. | Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist |
US5075341A (en) | 1989-12-01 | 1991-12-24 | The Mclean Hospital Corporation | Treatment for cocaine abuse |
US5086058A (en) | 1990-06-04 | 1992-02-04 | Alko Ltd. | Method for treating alcoholism with nalmefene |
FR2669336B1 (en) | 1990-11-20 | 1993-01-22 | Adir | NOVEL OXAZOLO PYRIDINES DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
HU208633B (en) | 1991-02-04 | 1993-12-28 | Alkaloida Vegyeszeti Gyar | Process for production of analgetic compositions as applicable for blocking of opioid-binding spaces /2-receptors/ causing respiration depression |
US5486362A (en) | 1991-05-07 | 1996-01-23 | Dynagen, Inc. | Controlled, sustained release delivery system for treating drug dependency |
JP3178541B2 (en) | 1991-05-29 | 2001-06-18 | キヤノン株式会社 | Image processing method and apparatus |
US5149538A (en) | 1991-06-14 | 1992-09-22 | Warner-Lambert Company | Misuse-resistive transdermal opioid dosage form |
KR100221695B1 (en) | 1991-08-12 | 1999-09-15 | 그린 마틴, 브라이언 쥐 테슬리 | Pharmaceutical spheroid formulation |
GB9117361D0 (en) | 1991-08-12 | 1991-09-25 | Euro Celtique Sa | Oral dosage form |
EP0566709B3 (en) | 1991-09-06 | 2009-04-08 | Ortho-McNeil-Janssen Pharmaceuticals, Inc. | Composition comprising a tramadol compound and acetaminophen, and its use |
US5215758A (en) | 1991-09-11 | 1993-06-01 | Euroceltique, S.A. | Controlled release matrix suppository for pharmaceuticals |
US5225440A (en) | 1991-09-13 | 1993-07-06 | The United States Of America As Represented By The Department Of Health And Human Services | Attenuation of the opioid withdrawal syndrome by inhibitors of nitric oxide synthase |
US5266331A (en) | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
US5656295A (en) | 1991-11-27 | 1997-08-12 | Euro-Celtique, S.A. | Controlled release oxycodone compositions |
US5472712A (en) | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
US5681585A (en) | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5958459A (en) | 1991-12-24 | 1999-09-28 | Purdue Pharma L.P. | Opioid formulations having extended controlled released |
US5478577A (en) | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
US5968551A (en) | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
US5286493A (en) | 1992-01-27 | 1994-02-15 | Euroceltique, S.A. | Stabilized controlled release formulations having acrylic polymer coating |
US5273760A (en) | 1991-12-24 | 1993-12-28 | Euroceltigue, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
GB9203689D0 (en) | 1992-02-20 | 1992-04-08 | Euro Celtique Sa | Pharmaceutical composition |
GB9204354D0 (en) | 1992-02-28 | 1992-04-08 | Biokine Tech Ltd | Compounds for medicinal use |
PT647137E (en) | 1992-06-22 | 2008-11-24 | Univ California | Glycine receptor antagonists and the use thereof |
US5352680A (en) | 1992-07-15 | 1994-10-04 | Regents Of The University Of Minnesota | Delta opioid receptor antagonists to block opioid agonist tolerance and dependence |
US5256669A (en) | 1992-08-07 | 1993-10-26 | Aminotek Sciences, Inc. | Methods and compositions for treating acute or chronic pain and drug addiction |
US5324351A (en) | 1992-08-13 | 1994-06-28 | Euroceltique | Aqueous dispersions of zein and preparation thereof |
US5512578A (en) * | 1992-09-21 | 1996-04-30 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists |
US5580876A (en) * | 1992-09-21 | 1996-12-03 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
US6096756A (en) | 1992-09-21 | 2000-08-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
US5472943A (en) * | 1992-09-21 | 1995-12-05 | Albert Einstein College Of Medicine Of Yeshiva University, | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists |
EP0668764A1 (en) | 1992-09-21 | 1995-08-30 | QIN, Bo-yi | Methods for identifying and using low/non-addictive opioid analgesics |
US5633259A (en) | 1992-09-21 | 1997-05-27 | United Biomedical, Inc. | Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction |
US20010006967A1 (en) | 1992-09-21 | 2001-07-05 | Stanley M. Crain | Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists |
US5869097A (en) | 1992-11-02 | 1999-02-09 | Alza Corporation | Method of therapy comprising an osmotic caplet |
US5604260A (en) | 1992-12-11 | 1997-02-18 | Merck Frosst Canada Inc. | 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 |
US5321012A (en) | 1993-01-28 | 1994-06-14 | Virginia Commonwealth University Medical College | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance |
US5585348A (en) | 1993-02-10 | 1996-12-17 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia |
US5352683A (en) | 1993-03-05 | 1994-10-04 | Virginia Commonwealth University Medical College Of Virginia | Method for the treatment of chronic pain |
CA2115792C (en) | 1993-03-05 | 2005-11-01 | David J. Mayer | Method for the treatment of pain |
US5409944A (en) | 1993-03-12 | 1995-04-25 | Merck Frosst Canada, Inc. | Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase |
IL119660A (en) | 1993-05-10 | 2002-09-12 | Euro Celtique Sa | Controlled release formulation comprising tramadol |
US5457208A (en) | 1993-06-21 | 1995-10-10 | Regents Of The University Of Minnesota | Kappa opioid receptor antagonists |
US5436265A (en) | 1993-11-12 | 1995-07-25 | Merck Frosst Canada, Inc. | 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents |
US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
IL110014A (en) | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
NZ260883A (en) | 1993-07-01 | 1997-06-24 | Euro Celtique Sa | Oral sustained-release medicaments containing morphine |
US5879705A (en) | 1993-07-27 | 1999-03-09 | Euro-Celtique S.A. | Sustained release compositions of morphine and a method of preparing pharmaceutical compositions |
DE4325465B4 (en) | 1993-07-29 | 2004-03-04 | Zenz, Michael, Prof. Dr.med. | Oral pharmaceutical preparation for pain therapy |
GB9319568D0 (en) | 1993-09-22 | 1993-11-10 | Euro Celtique Sa | Pharmaceutical compositions and usages |
EP1442745A1 (en) | 1993-10-07 | 2004-08-04 | Euro-Celtique | Orally administrable opioid formulations having extended duration of effect |
US5500227A (en) | 1993-11-23 | 1996-03-19 | Euro-Celtique, S.A. | Immediate release tablet cores of insoluble drugs having sustained-release coating |
US6210714B1 (en) | 1993-11-23 | 2001-04-03 | Euro-Celtique S.A. | Immediate release tablet cores of acetaminophen having sustained-release coating |
ATE212224T1 (en) | 1993-11-23 | 2002-02-15 | Euro Celtique Sa | METHOD FOR PRODUCING A MEDICINAL COMPOSITION WITH DELAYED RELEASE |
US5891471A (en) | 1993-11-23 | 1999-04-06 | Euro-Celtique, S.A. | Pharmaceutical multiparticulates |
KR100354702B1 (en) | 1993-11-23 | 2002-12-28 | 유로-셀티크 소시에떼 아노뉨 | Manufacturing method and sustained release composition of pharmaceutical composition |
US5376662A (en) | 1993-12-08 | 1994-12-27 | Ockert; David M. | Method of attenuating nerve injury induced pain |
US5834477A (en) | 1993-12-08 | 1998-11-10 | The United States Of America As Represented By The Secretary Of The Army | Opiate analgesic formulation with improved safety |
US5843480A (en) | 1994-03-14 | 1998-12-01 | Euro-Celtique, S.A. | Controlled release diamorphine formulation |
US5411745A (en) | 1994-05-25 | 1995-05-02 | Euro-Celtique, S.A. | Powder-layered morphine sulfate formulations |
US6077533A (en) | 1994-05-25 | 2000-06-20 | Purdue Pharma L.P. | Powder-layered oral dosage forms |
US5460826A (en) | 1994-06-27 | 1995-10-24 | Alza Corporation | Morphine therapy |
GB9414699D0 (en) * | 1994-07-21 | 1994-09-07 | Slagel David | Aqueous foamable composition |
US5616601A (en) | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
US5521213A (en) | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
US5593994A (en) | 1994-09-29 | 1997-01-14 | The Dupont Merck Pharmaceutical Company | Prostaglandin synthase inhibitors |
US5866154A (en) | 1994-10-07 | 1999-02-02 | The Dupont Merck Pharmaceutical Company | Stabilized naloxone formulations |
GB9422154D0 (en) | 1994-11-03 | 1994-12-21 | Euro Celtique Sa | Pharmaceutical compositions and method of producing the same |
US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
CA2206119C (en) | 1994-12-12 | 2008-05-13 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain, inflammation and spasm |
GB9426102D0 (en) | 1994-12-23 | 1995-02-22 | Merck Sharp & Dohme | Pharmacuetical compositions |
US5692500A (en) | 1995-01-09 | 1997-12-02 | Gaston-Johansson; Fannie | Pain measurement and recording tool and method |
US5552422A (en) | 1995-01-11 | 1996-09-03 | Merck Frosst Canada, Inc. | Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents |
US5578725A (en) | 1995-01-30 | 1996-11-26 | Regents Of The University Of Minnesota | Delta opioid receptor antagonists |
BE1009257A3 (en) * | 1995-03-21 | 1997-01-07 | Universiteit Gent Lab Voor Far | Pharmaceutical matrix. |
US20020006964A1 (en) | 1995-05-16 | 2002-01-17 | Young James W. | Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds |
US5604253A (en) | 1995-05-22 | 1997-02-18 | Merck Frosst Canada, Inc. | N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors |
US5639780A (en) | 1995-05-22 | 1997-06-17 | Merck Frosst Canada, Inc. | N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors |
US5510368A (en) | 1995-05-22 | 1996-04-23 | Merck Frosst Canada, Inc. | N-benzyl-3-indoleacetic acids as antiinflammatory drugs |
CN1156961A (en) | 1995-06-09 | 1997-08-13 | 欧罗赛铁克股份有限公司 | Formulations and method for providing prolonged local anesthesia |
US5931809A (en) | 1995-07-14 | 1999-08-03 | Depotech Corporation | Epidural administration of therapeutic compounds with sustained rate of release |
GB9517883D0 (en) | 1995-09-01 | 1995-11-01 | Euro Celtique Sa | Improved pharmaceutical ion exchange resin composition |
GB9519363D0 (en) | 1995-09-22 | 1995-11-22 | Euro Celtique Sa | Pharmaceutical formulation |
US5811126A (en) | 1995-10-02 | 1998-09-22 | Euro-Celtique, S.A. | Controlled release matrix for pharmaceuticals |
AUPN603895A0 (en) | 1995-10-19 | 1995-11-09 | University Of Queensland, The | Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids |
US5998434A (en) | 1995-12-06 | 1999-12-07 | Eli Lilly And Company | Composition for treating pain |
EP0888111B1 (en) * | 1996-03-08 | 2003-05-21 | Nycomed Danmark A/S | Modified release multiple-units dosage composition |
DE69709646T2 (en) | 1996-03-12 | 2002-08-14 | Alza Corp | COMPOSITION AND DOSAGE WITH AN OPIOID ANTAGONIST |
US6103258A (en) | 1996-04-12 | 2000-08-15 | Simon; David Lew | Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics |
WO1997045091A2 (en) | 1996-05-31 | 1997-12-04 | Euro-Celtique, S.A. | Sustained release oxycodone formulations with no fed/fast effect |
DE19651551C2 (en) | 1996-12-11 | 2000-02-03 | Klinge Co Chem Pharm Fab | Opioid antagonist-containing galenic formulation |
WO1998035679A1 (en) | 1997-02-14 | 1998-08-20 | Gödecke Aktiengesellschaft | Stabilization of naloxonhydrochlorid |
DE29719704U1 (en) | 1997-02-14 | 1998-01-22 | Goedecke Ag | Stable preparations of naloxone hydrochloride |
US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
DE19710008A1 (en) | 1997-03-12 | 1998-09-17 | Basf Ag | Solid, at least two-phase formulations of a sustained-release opioid analgesic |
US5780479A (en) | 1997-04-04 | 1998-07-14 | Regents Of The University Of Minnesota | Use of opioid antagonists to treat impulse-control disorders |
US6207142B1 (en) | 1997-04-14 | 2001-03-27 | Janssen Pharmaceutica N.V. | Compositions containing an antifungal and a cationic agent |
AU8293498A (en) | 1997-07-02 | 1999-01-25 | Euro-Celtique S.A. | Stabilized sustained release tramadol formulations |
WO1999005960A1 (en) | 1997-07-30 | 1999-02-11 | Universite De Montreal | Portable and programmable interactive visual analogue scale data-logger device |
EP1009407B1 (en) | 1997-09-04 | 2004-04-28 | Novoneuron, Inc. | Noribogaine in the treatment of pain and drug addiction |
US6066339A (en) * | 1997-10-17 | 2000-05-23 | Elan Corporation, Plc | Oral morphine multiparticulate formulation |
EP0913152B1 (en) | 1997-11-03 | 2001-12-19 | Stada Arzneimittel Ag | Stabilised combination of drugs comprising naloxone and an opioid analgesic |
US5972954A (en) | 1997-11-03 | 1999-10-26 | Arch Development Corporation | Use of methylnaltrexone and related compounds |
US6274591B1 (en) | 1997-11-03 | 2001-08-14 | Joseph F. Foss | Use of methylnaltrexone and related compounds |
US6375957B1 (en) * | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
UA53774C2 (en) * | 1997-12-22 | 2003-02-17 | Еро-Селтік, С.А. | Method of reducing abuse potential of an oral dosage form of opioid analgesic |
WO1999032119A1 (en) | 1997-12-22 | 1999-07-01 | Euro-Celtique, S.A. | Opioid agonist/antagonist combinations |
BR9908953A (en) | 1998-03-27 | 2000-12-05 | Upjohn Co | Use of cabergoline in the treatment of restless legs syndrome (ekbom syndrome) |
DE19857766A1 (en) | 1998-05-28 | 1999-12-02 | Krewel Meuselbach Gmbh | Delayed pain reliever containing tilidine |
SE9803760D0 (en) | 1998-11-04 | 1998-11-04 | Jan Hedner | Methods to treat and diagnose the restless legs syndrome and the corresponding agents |
DE19859636A1 (en) | 1998-12-23 | 2000-06-29 | Hexal Ag | Controlled release pharmaceutical composition with tilidine mesylate as active ingredient |
FR2787715B1 (en) | 1998-12-23 | 2002-05-10 | Synthelabo | PHARMACEUTICAL COMPOSITION COMPRISING A HYPNOTIC COMPOUND OR ONE OF ITS PHARMACEUTICALLY ACCEPTABLE SALTS |
DE19901085C2 (en) | 1999-01-14 | 2003-12-18 | Lohmann Therapie Syst Lts | Transdermal therapeutic system with a self-adhesive matrix containing organic acid addition salts of morphine or morphine type alkaloids |
US6194382B1 (en) | 1999-03-03 | 2001-02-27 | Albert Einstein College Of Medicine Of Yeshiva University | Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists |
DE19918325A1 (en) | 1999-04-22 | 2000-10-26 | Euro Celtique Sa | Extruded drug dosage form, e.g. granulate for tableting, comprising an active agent in a polysaccharide-containing matrix, giving a release profile which is controllable by extrusion conditions and/or the inclusion of additives |
US6765010B2 (en) | 1999-05-06 | 2004-07-20 | Pain Therapeutics, Inc. | Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects |
US20030178031A1 (en) | 1999-05-07 | 2003-09-25 | Du Pen, Inc. | Method for cancer pain treatment |
US20030118641A1 (en) | 2000-07-27 | 2003-06-26 | Roxane Laboratories, Inc. | Abuse-resistant sustained-release opioid formulation |
US6451007B1 (en) * | 1999-07-29 | 2002-09-17 | Dale E. Koop | Thermal quenching of tissue |
DE19938823A1 (en) | 1999-08-19 | 2001-02-22 | Boehringer Ingelheim Pharma | Treatment of restless leg syndrome symptoms, using synergistic combination of alpha-2 agonist, preferably clonidine, and another neuro-psychic drug, e.g. pramipexol |
US6258042B1 (en) | 1999-09-17 | 2001-07-10 | James S. Factor | Visual analog scale and method of use for the diagnosis and/or treatment of physical pain |
US6451806B2 (en) * | 1999-09-29 | 2002-09-17 | Adolor Corporation | Methods and compositions involving opioids and antagonists thereof |
DE60013630T2 (en) | 1999-11-01 | 2005-09-15 | John Cardiff Rhodes | MEDICAMENT FOR THE TREATMENT OF DARMING AND IRRITATION |
DK1244447T3 (en) | 1999-11-29 | 2007-04-23 | Adolor Corp | New methods and compositions containing opioids and their antagonists |
JP2001174985A (en) * | 1999-12-15 | 2001-06-29 | Sumitomo Chem Co Ltd | Pigment dispersed photosensitive fluid, method for producing same and colored image forming method using same |
WO2001052851A1 (en) | 2000-01-22 | 2001-07-26 | Albert Shulman | Methods for the treatment of substance abuse |
US6716449B2 (en) * | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
HU229705B1 (en) | 2000-02-08 | 2014-05-28 | Euro Celtique Sa | Tamper-resistant oral opioid agonist formulations |
AU4743601A (en) | 2000-03-15 | 2001-09-24 | Wolfgang Sadee | Neutral antagonists and use thereof in treating drug abuse |
WO2001085257A2 (en) | 2000-05-05 | 2001-11-15 | Pain Therapeutics, Inc. | Opioid antagonist compositions and dosage forms |
WO2001085150A2 (en) | 2000-05-05 | 2001-11-15 | Pain Therapeutics, Inc. | Opioid antagonist containing composition for enchaching the potency or reducing adverse side effects ofopioid agonists |
US6525062B2 (en) | 2000-06-09 | 2003-02-25 | The Regents Of The University Of California | Method of treating pain using nalbuphine and opioid antagonists |
US7223421B2 (en) | 2000-06-30 | 2007-05-29 | Mcneil-Ppc, Inc. | Teste masked pharmaceutical particles |
GB0026137D0 (en) | 2000-10-25 | 2000-12-13 | Euro Celtique Sa | Transdermal dosage form |
AR031152A1 (en) | 2000-10-31 | 2003-09-10 | Upjohn Co | NEW TREATMENTS FOR THE CONCERNED LEG SYNDROME |
KR100618743B1 (en) | 2001-04-19 | 2006-08-31 | 워너-램버트 캄파니 엘엘씨 | Fused bicyclic or tricyclic amino acids |
UA81224C2 (en) | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Dosage form of oxycodone and use thereof |
ES2275868T3 (en) | 2001-05-11 | 2007-06-16 | Endo Pharmaceuticals Inc. | OPIOID DOSAGE FORM TO PREVENT ABUSIVE CONSUMPTION. |
ATE493130T1 (en) * | 2001-05-11 | 2011-01-15 | Endo Pharmaceuticals Inc | MEDICINAL FORM CONTAINING OPIOID AGAINST ABUSE |
DE10131113A1 (en) | 2001-06-28 | 2003-01-23 | Siemens Linear Motor Systems G | Rotary electric motor |
US20030021841A1 (en) | 2001-07-02 | 2003-01-30 | Matharu Amol Singh | Pharmaceutical composition |
DE60230632D1 (en) | 2001-07-18 | 2009-02-12 | Euro Celtique Sa | PHARMACEUTICAL COMBINATIONS OF OXYCODONE AND NALOXONE |
ATE431738T1 (en) * | 2001-08-06 | 2009-06-15 | Euro Celtique Sa | OPIOID AGONIST FORMULATIONS WITH RELEASABLE AND SEQUESTRED ANTAGONIST |
WO2003013433A2 (en) | 2001-08-06 | 2003-02-20 | Euro-Celtique S.A. | Sequestered antagonist formulations |
US20030044458A1 (en) | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
US7332182B2 (en) * | 2001-08-06 | 2008-02-19 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant |
MXPA04001206A (en) | 2001-08-06 | 2004-07-08 | Euro Celtique Sa | Compositions and methods to prevent abuse of opioids. |
KR20040060917A (en) | 2001-08-06 | 2004-07-06 | 유로-셀티크 소시에떼 아노뉨 | Compositions and methods to prevent abuse of opioids |
ATE426429T1 (en) | 2001-09-06 | 2009-04-15 | Hans Gregersen | BALLOON CATHETER SYSTEM FOR STIMULATION AND MEASURING THE RESPONSE PRODUCED BY STIMULI |
US20040253310A1 (en) | 2001-09-21 | 2004-12-16 | Gina Fischer | Morphine polymer release system |
EP1429739A1 (en) | 2001-09-21 | 2004-06-23 | Egalet A/S | Polymer release system |
CA2461539A1 (en) | 2001-09-24 | 2003-04-03 | Faruk S. Abuzzahab, Sr. | Anticonvulsant derivatives useful for the treatment of restless limb syndrome and periodic limb movement disorder |
US20040033253A1 (en) | 2002-02-19 | 2004-02-19 | Ihor Shevchuk | Acyl opioid antagonists |
PT1482835E (en) | 2002-03-06 | 2012-12-26 | Euro Celtique Sa | Analog scale for measuring pain |
WO2003077867A2 (en) | 2002-03-14 | 2003-09-25 | Euro-Celtique, S.A. | Naltrexone hydrochloride compositions |
EP2243471A1 (en) | 2002-04-05 | 2010-10-27 | Euro-Celtique S.A. | Matrix for sustained, invariant and independent release of active compounds |
US20030191147A1 (en) | 2002-04-09 | 2003-10-09 | Barry Sherman | Opioid antagonist compositions and dosage forms |
EP1364649A1 (en) | 2002-05-23 | 2003-11-26 | Cilag AG | Adduct of topiramate and tramadol hydrochioride and uses thereof |
JP4694207B2 (en) | 2002-07-05 | 2011-06-08 | コルジウム ファーマシューティカル, インコーポレイテッド | Abuse deterrent pharmaceutical compositions for opioids and other drugs |
RU2222260C1 (en) | 2002-07-08 | 2004-01-27 | Сибирский государственный медицинский университет | Method for carrying out differential evaluation of functional activity degree of small intestine |
JP5189242B2 (en) | 2002-09-23 | 2013-04-24 | アルケルメス ファーマ アイルランド リミテッド | Abuse-resistant pharmaceutical composition |
CN100500130C (en) | 2003-01-23 | 2009-06-17 | 株式会社太平洋 | Sustained-release preparations and method for producing the same |
CN104383542B (en) | 2003-04-08 | 2017-09-26 | 普罗热尼奇制药公司 | Pharmaceutical formulation comprising methyl naltrexone |
TWI357815B (en) | 2003-06-27 | 2012-02-11 | Euro Celtique Sa | Multiparticulates |
US20050053659A1 (en) | 2003-09-10 | 2005-03-10 | Pace Gary W. | Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness |
TWI350762B (en) | 2004-02-12 | 2011-10-21 | Euro Celtique Sa | Particulates |
WO2006079550A2 (en) | 2005-01-28 | 2006-08-03 | Euro-Celtique S.A. | Alcohol resistant dosage forms |
KR101053558B1 (en) * | 2004-03-30 | 2011-08-03 | 유로-셀띠끄 소시에떼 아노님 | Tamper resistant dosage form comprising an adsorbent and an adverse agent |
US7700626B2 (en) | 2004-06-04 | 2010-04-20 | Adolor Corporation | Compositions containing opioid antagonists |
EP1604667A1 (en) | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the restless leg syndrome |
EP1604666A1 (en) | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD) |
GB2418854B (en) | 2004-08-31 | 2009-12-23 | Euro Celtique Sa | Multiparticulates |
EP1695700A1 (en) | 2005-02-28 | 2006-08-30 | Euro-Celtique S.A. | Dosage form containing oxycodone and naloxone |
EP1702558A1 (en) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Method and device for the assessment of bowel function |
US20070092576A1 (en) | 2005-10-20 | 2007-04-26 | Adolor Corporation | Compositions containing opioid antagonists |
EP1813276A1 (en) | 2006-01-27 | 2007-08-01 | Euro-Celtique S.A. | Tamper resistant dosage forms |
US20070185145A1 (en) | 2006-02-03 | 2007-08-09 | Royds Robert B | Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same |
WO2007111945A2 (en) | 2006-03-22 | 2007-10-04 | Trustees Of Boston University | Method for management of diarrhea |
EP2012790A4 (en) | 2006-04-19 | 2009-07-01 | Smith Jill P | Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists |
DE202006018609U1 (en) | 2006-08-29 | 2007-05-16 | Euro-Celtique S.A. | Needle-free apparatus for administrating pharmaceutical composition in humans, comprises a housing; auxiliary substance to force a pharmaceutical composition from a package into human body; a composition comprising analgesic, e.g. opioids |
TW200817048A (en) | 2006-09-08 | 2008-04-16 | Wyeth Corp | Dry powder compound formulations and uses thereof |
EP2042176A1 (en) | 2007-09-26 | 2009-04-01 | Euro-Celtique S.A. | Use of a combination of an opioid agonist and an opioid antagonist for the treatment of Crohn's disease |
BRPI0910780A2 (en) | 2008-07-07 | 2016-08-09 | Euro Celtique Sa | use of opioid antagonists for the treatment of urinary retention |
DK2405915T3 (en) | 2009-03-10 | 2019-02-11 | Euro Celtique Sa | PHARMACEUTICAL COMPOSITIONS WITH IMMEDIATE RELEASE INCLUDING OXYCODON AND NALOXON |
CH705678B1 (en) | 2010-08-13 | 2016-03-15 | Euro Celtique Sa | Use of binders for the production of storage-stable formulations. |
-
2002
- 2002-05-10 AT AT02734389T patent/ATE493130T1/en not_active IP Right Cessation
- 2002-05-10 DE DE60238756T patent/DE60238756D1/en not_active Expired - Lifetime
- 2002-05-10 CA CA2446550A patent/CA2446550C/en not_active Expired - Lifetime
- 2002-05-10 AU AU2002305559A patent/AU2002305559B2/en not_active Expired
- 2002-05-10 WO PCT/US2002/015022 patent/WO2002092060A1/en active Application Filing
- 2002-05-10 ES ES02734389T patent/ES2361148T3/en not_active Expired - Lifetime
- 2002-05-10 CN CNA028097297A patent/CN1525851A/en active Pending
- 2002-05-10 US US10/143,111 patent/US20030065002A1/en not_active Abandoned
- 2002-05-10 JP JP2002588978A patent/JP4522652B2/en not_active Expired - Lifetime
- 2002-05-10 EP EP02734389A patent/EP1387673B1/en not_active Expired - Lifetime
-
2007
- 2007-09-14 US US11/901,232 patent/US20080069881A1/en not_active Abandoned
-
2008
- 2008-07-03 AU AU2008202967A patent/AU2008202967B2/en not_active Expired
-
2009
- 2009-01-28 JP JP2009017380A patent/JP2009102405A/en active Pending
-
2012
- 2012-06-12 US US13/494,431 patent/US20120252832A1/en not_active Abandoned
- 2012-09-18 JP JP2012204455A patent/JP5765820B2/en not_active Expired - Lifetime
-
2013
- 2013-02-26 US US13/777,537 patent/US20130172382A1/en not_active Abandoned
- 2013-10-30 US US14/067,821 patent/US9084729B2/en not_active Expired - Fee Related
- 2013-12-20 US US14/136,443 patent/US8969369B2/en not_active Expired - Fee Related
-
2014
- 2014-03-11 US US14/205,204 patent/US9056051B2/en not_active Expired - Fee Related
- 2014-06-19 JP JP2014125979A patent/JP5977784B2/en not_active Expired - Lifetime
-
2015
- 2015-05-29 US US14/725,379 patent/US9168252B2/en not_active Expired - Fee Related
- 2015-05-29 US US14/725,369 patent/US9161937B2/en not_active Expired - Fee Related
- 2015-05-29 JP JP2015110130A patent/JP6203782B2/en not_active Expired - Lifetime
- 2015-09-18 US US14/859,200 patent/US9283221B2/en not_active Expired - Fee Related
- 2015-09-18 US US14/859,195 patent/US9283216B2/en not_active Expired - Fee Related
-
2016
- 2016-02-03 US US15/014,995 patent/US9358230B1/en not_active Expired - Lifetime
- 2016-02-03 US US15/015,019 patent/US9345701B1/en not_active Expired - Lifetime
- 2016-05-19 US US15/159,737 patent/US9480685B2/en not_active Expired - Lifetime
- 2016-05-19 US US15/159,465 patent/US9511066B2/en not_active Expired - Lifetime
- 2016-09-29 US US15/280,541 patent/US20170014405A1/en not_active Abandoned
- 2016-09-29 US US15/280,621 patent/US20170014406A1/en not_active Abandoned
- 2016-10-05 JP JP2016196952A patent/JP2016222732A/en not_active Withdrawn
-
2018
- 2018-02-09 JP JP2018022019A patent/JP2018080209A/en active Pending
- 2018-02-15 US US15/898,018 patent/US20180185353A1/en not_active Abandoned
- 2018-02-15 US US15/898,069 patent/US20180169090A1/en not_active Abandoned
- 2018-12-17 US US16/222,720 patent/US20190111051A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2446550A1 (en) | Abuse-resistant controlled-release opioid dosage form | |
AU2002305559A1 (en) | Abuse-resistant controlled-release opioid dosage form | |
US20070281016A1 (en) | Sustained release oxycodone composition with acrylic polymer and surfactant | |
US20070281017A1 (en) | Sustained release oxycodone composition with acrylic polymer and metal hydroxide | |
AU2017200011A1 (en) | Abuse-Resistant Controlled-Release Opioid Dosage Form | |
AU2013270469B2 (en) | Abuse-Resistant Controlled-Release Opioid Dosage Form | |
AU2012200034B2 (en) | Abuse-Resistant Controlled-Release Opioid Dosage Form |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20220510 |